POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
115 hedge funds and large institutions have $455M invested in POINT Biopharma Global Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 13 closing their positions.
6,500% more call options, than puts
Call options by funds: $66K | Put options by funds: $1K
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6% more funds holding
Funds holding: 109 → 115 (+6)
2% more capital invested
Capital invested by funds: $446M → $455M (+$9.47M)
8% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$17.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$10.3M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
+$6.4M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.24M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$19.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.64M |
| 4 |
PA
Perceptive Advisors
New York
|
-$3.65M |
| 5 |
Millennium Management
New York
|
-$2.15M |
PNT Hedge Fund Activity: Q1 2023 in Review
115 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q1 2023, worth a combined $455M — up 2.1% from $446M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PNT positions and 13 closed out — a net gain of 6 holders — while 34 added to existing stakes and 37 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $17.4M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $19.2M sold.
- 115 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q1 2023, up from 109 in Q4 2022.
- Funds reported $455M of POINT Biopharma Global Inc. Common Stock stock for Q1 2023, up 2.1% quarter-over-quarter.
- 19 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q1 2023 and 13 closed out, a net change of +6 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q1 2023 was Deep Track Capital, an estimated $17.4M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q1 2023 was Suvretta Capital Management, an estimated $19.2M sold.
Based on aggregated 13F filings for Q1 2023.